Overview

Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
0
Participant gender:
All
Summary
In this study the investigators are going to evaluate the efficacy pentoxifyline in HTLV-1 patients with neurological diseases: HAM/TSP or neurogenic bladder. In some laboratory experiments the investigators observed that this drug had the capacity to reduce the immune response in HTLV-1 infected cells. Since the exacerbated immune response is know to cause neurological disease in patients with HTLV-1 the investigators hope that pentoxifyline can alleviate symptoms and delay the progress of HAM/TSP in patients.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hospital Universitário Professor Edgard Santos
Treatments:
Pentoxifylline
Criteria
Inclusion Criteria:

- Age ≥ 18 and ≤ 80 years;

- Confirmed HTLV-1 infection with Western Blot analysis;

- HAM/TSP diagnosed patients according to the WHO

- Patients with HTLV-1 and neurogenic bladder diagnosed by clinical and urodynamic study

- Disease duration < 5 years

Exclusion Criteria:

- Neurological diseases with functional limitations.

- Co-infection with Hepatitis B or C, Syphilis, Chagas Disease or HIV

- Use of immunossupressive drugs

- Immune disease

- Pregnancy